Coya Therapeutics, Inc. (COYA)Healthcare | Biotechnology | Houston, United States | NasdaqCM
4.34 USD
+0.16
(3.828%)
⇧
(Oct. 15, 2026, 4 p.m.
EDT)
|
Hot Take ↕ | Oct. 10, 2026, 2:22 a.m. EDT
The investment case here is defined by a stark disconnect between aggressive analyst targets and the company's deteriorating financial reality. While analysts project a mean price of $15.21, the fundamentals tell a different story: the company is burning cash rapidly with negative operating margins of nearly 29%, negative gross margins, and no path to profitability visible in the trailing twelve months. The balance sheet is fragile, with free cash flow draining reserves and no dividend support. The recent price action shows a slight recovery from a low point, but the underlying business metrics—specifically the massive losses and lack of revenue scale—suggest the market is pricing in a high-risk turnaround scenario rather than sustainable growth. The options market confirms this ambiguity with minimal liquidity and mixed signals, offering no clear directional bias. Until the ALS trial readout in 2027 provides definitive proof of concept, the risk of capital erosion remains high despite the optimistic analyst consensus. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.070389 |
| AutoARIMA | 0.076737 |
| AutoETS | 0.076774 |
| AutoTheta | 0.086943 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 39% |
| H-stat | 2.08 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.108 |
| Excess Kurtosis | 0.67 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Revenue per Share | 0.403 |
| Market Cap | 101,807,064 |
| Forward P/E | -2.26 |
| Beta | 0.58 |
| Profit Margins | -270.22% |
| Website | https://www.coyatherapeutics.com |
As of Oct. 10, 2026, 2:22 a.m. EDT: Speculator positioning is extremely thin and ambiguous. Call volume is heavily skewed toward out-of-the-money strikes (7.5) suggesting a speculative hope for a catalyst-driven spike, while the bulk of actual traded volume sits at the money. Put activity is negligible, indicating a lack of organized hedging or bearish conviction. Implied volatility is elevated relative to the low trading volume, reflecting uncertainty rather than a clear directional bet.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.31761009 |
| Address1 | 5,850 San Felipe St. |
| Address2 | Suite 500 |
| All Time High | 10.69 |
| All Time Low | 3.21 |
| Ask | 4.51 |
| Ask Size | 3 |
| Average Analyst Rating | 1.0 - Strong Buy |
| Average Daily Volume10 Day | 149,530 |
| Average Daily Volume3 Month | 144,248 |
| Average Volume | 144,248 |
| Average Volume10Days | 149,530 |
| Beta | 0.579 |
| Bid | 4.48 |
| Bid Size | 1 |
| Book Value | 1.845 |
| City | Houston |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 4.34 |
| Current Ratio | 13.397 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 4.5 |
| Day Low | 4.16 |
| Display Name | Coya Therapeutics |
| Dividend Yield | 0.0 |
| Earnings Timestamp | 1,786,451,400 |
| Earnings Timestamp End | 1,794,400,200 |
| Earnings Timestamp Start | 1,794,400,200 |
| Ebitda | -20,830,436 |
| Ebitda Margins | -2.59759 |
| Enterprise To Ebitda | -2.814 |
| Enterprise To Revenue | 7.311 |
| Enterprise Value | 58,626,064 |
| Eps Current Year | -1.36667 |
| Eps Forward | -1.92 |
| Eps Trailing Twelve Months | -1.07 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 4.7675 |
| Fifty Day Average Change | -0.42749977 |
| Fifty Day Average Change Percent | -0.08966959 |
| Fifty Two Week Change Percent | -31.76101 |
| Fifty Two Week High | 7.55 |
| Fifty Two Week High Change | -3.21 |
| Fifty Two Week High Change Percent | -0.42516556 |
| Fifty Two Week Low | 3.71 |
| Fifty Two Week Low Change | 0.6300001 |
| Fifty Two Week Low Change Percent | 0.16981135 |
| Fifty Two Week Range | 3.71 - 7.55 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,672,324,200,000 |
| Float Shares | 17,543,422 |
| Forward Eps | -1.92 |
| Forward P E | -2.2604167 |
| Free Cashflow | -10,944,188 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 8 |
| Fullday Change | 0.16000032 |
| Fullday Change Percent | 3.827759 |
| Fullday Price | 4.34 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | -1.11801 |
| Gross Profits | -8,965,472 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.1469 |
| Held Percent Institutions | 0.3326 |
| Implied Shares Outstanding | 23,457,849 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,022-12-29 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary therapies to enhance the function of regulatory T cells (Tregs). Its candidate product pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. The company develops COYA 302, a biologic combination for subcutaneous administration intended to enhance Treg function while depleting T effector function and activated macrophages in Phase 2 trial for use in the treatment of amyotrophic lateral sclerosis, as well as frontotemporal dementia, Alzheimer's disease (AD), and Parkinson's disease. In addition, its pre-clinical product candidates include COYA 301, a low-dose interleukin 2 product candidate to treat AD; COYA 303, an investigational biologic combination of COYA 301 and a glucagon-like-peptide-1 receptor agonist for the treatment of inflammatory diseases; COYA 201, an antigen directed Treg-derived exosome product candidate to treat neurodegenerative, autoimmune, and metabolic diseases; COYA 206, an antigen directed Treg-derived exosome product candidate; and COYA 101. It has a collaboration with Dr. Reddy's Laboratories SA for the development and commercialization of COYA 302, an investigational combination therapy for treatment of amyotrophic lateral sclerosis. Coya Therapeutics, Inc. was founded in 2020 and is headquartered in Houston, Texas. |
| Long Name | Coya Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 101,807,064 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_700238507 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -21,669,624 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 118,696,715 |
| Number Of Analyst Opinions | 7 |
| Open | 4.1826 |
| Operating Cashflow | -15,722,176 |
| Operating Margins | -28.904518 |
| Phone | 800 587 8170 |
| Previous Close | 4.18 |
| Price Eps Current Year | -3.1756022 |
| Price Hint | 4 |
| Price To Book | 2.3523035 |
| Price To Sales Trailing12 Months | 12.695501 |
| Profit Margins | -2.70224 |
| Quick Ratio | 12.294 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.0 |
| Region | US |
| Regular Market Change | 0.16 |
| Regular Market Change Percent | 3.82776 |
| Regular Market Day High | 4.5 |
| Regular Market Day Low | 4.16 |
| Regular Market Day Range | 4.16 - 4.5 |
| Regular Market Open | 4.1826 |
| Regular Market Previous Close | 4.18 |
| Regular Market Price | 4.34 |
| Regular Market Time | 1,792,094,401 |
| Regular Market Volume | 236,120 |
| Return On Assets | -0.32271 |
| Return On Equity | -0.60541 |
| Revenue Growth | 0.49 |
| Revenue Per Share | 0.403 |
| Sand P52 Week Change | 0.16207206 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 23,457,849 |
| Shares Percent Shares Out | 0.0508 |
| Shares Short | 1,191,391 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 1,085,717 |
| Short Name | Coya Therapeutics, Inc. |
| Short Percent Of Float | 0.0513 |
| Short Ratio | 8.48 |
| Source Interval | 15 |
| State | TX |
| Symbol | COYA |
| Target High Price | 18.0 |
| Target Low Price | 12.0 |
| Target Mean Price | 15.21429 |
| Target Median Price | 15.5 |
| Total Cash | 43,181,000 |
| Total Cash Per Share | 1.841 |
| Total Debt | 0 |
| Total Revenue | 8,019,145 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.07 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 4.7031 |
| Two Hundred Day Average Change | -0.36310005 |
| Two Hundred Day Average Change Percent | -0.077204406 |
| Type Disp | Equity |
| Volume | 236,120 |
| Website | https://www.coyatherapeutics.com |
| Zip | 77,057 |